Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
70.37 USD | -0.89% | -2.96% | -1.47% |
Financials (USD)
Sales 2024 * | 137M | Sales 2025 * | 158M | Capitalization | 1.26B |
---|---|---|---|---|---|
Net income 2024 * | 28M | Net income 2025 * | 52M | EV / Sales 2024 * | 9.15 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.97 x |
P/E ratio 2024 * |
42.4
x | P/E ratio 2025 * |
24.8
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.07% |
Latest transcript on Ligand Pharmaceuticals Incorporated
1 day | +1.60% | ||
1 week | -9.98% | ||
Current month | -2.87% | ||
3 months | -4.27% | ||
6 months | +36.83% | ||
Current year | -0.59% |
Managers | Title | Age | Since |
---|---|---|---|
Todd Davis
CEO | Chief Executive Officer | 63 | 07-02-28 |
Octavio Espinoza
DFI | Director of Finance/CFO | 53 | 22-10-31 |
President | 49 | 15-08-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
John W. Kozarich
CHM | Chairman | 74 | 03-02-28 |
John LaMattina
BRD | Director/Board Member | 74 | 11-01-31 |
Stephen Sabba
BRD | Director/Board Member | 64 | 08-08-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.24% | 27 M€ | -4.43% | - | |
0.14% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 70.37 | -0.89% | 106 715 |
24-04-24 | 71 | +1.59% | 152,962 |
24-04-23 | 69.89 | +1.98% | 140,672 |
24-04-22 | 68.53 | -5.44% | 247,324 |
24-04-19 | 72.47 | -0.07% | 137,196 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.59% | 1.26B | |
+25.61% | 660B | |
+23.21% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+12.74% | 219B | |
-9.69% | 196B | |
+6.66% | 199B | |
-8.75% | 149B |
- Stock Market
- Equities
- LGND Stock